Spontaneous T cell responses against cancer neoantigens

Project Information

NeoTs

Grant agreement ID: 882963

DOI 10.3030/882963

EC signature date 23 July 2020

Start date 1 October 2020

End date 30 September 2026

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 2 499 573,75

EU contribution € 2 499 573,75

Coordinated by

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Germany

Publications

Peer reviewed articles (6)

Targeting the recurrent Rac1P29Sneoepitope in melanoma withheterologous high-affinityT cell receptors

Author(s): Lena Immisch1,2,3, George Papafotiou1,2,3, Nerea Galları´n Delgado1, Vivian Scheuplein4, Annette Paschen5,6, Thomas Blankenstein4,7† and Gerald Willimsky1,2,3,7
Published in: Frontiers in Immunology, 2023, ISSN 1664-3224
Publisher: Frontiers Media
DOI: 10.3389/fimmu.2023.1119498

IFNγ binding to extracellular matrix prevents fatal systemic toxicity

Author(s): Josephine Kemna 1 , Evelyne Gout    2 , Leon Daniau 3,4 , Jessica Lao 3,4 , Kristoffer Weißert    3,4,5 , Sandra Ammann    3,5 , Ralf Kühn    6 , Matthias Richter    7 , Christine Molenda    7 , Anje Sporbert 7 , Dario Zocholl    8 , Robert Klopfleisch 9 , Hugues Lortat-Jacob    2 , Peter Aichele    3,5 , Thomas Kammertoens 1,10,11 & Thomas Blank
Published in: Nature Immunology, 2022, ISSN 1529-2908
Publisher: Nature Publishing Group
DOI: 10.1038/s41590-023-01420-5

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2sup+/suppatients with diffuse midline glioma.

Author(s): Lena Immisch; George Papafotiou; Oliver Popp; Philipp Mertins; Thomas Blankenstein; Gerald Willimsky
Published in: J Immunother Cancer, 2022, ISSN 2051-1426
Publisher: BMJ
DOI: 10.1136/jitc-2022-005535

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy

Author(s): Natalia Plewa; Lucia Poncette; Thomas Blankenstein
Published in: J Immunother Cancer, 2023, ISSN 2051-1426
Publisher: BMJ
DOI: 10.1136/jitc-2022-006001

The role of CD4 T cells in rejection of solid tumors.

Author(s): Lucia Poncette; Julia Bluhm; Thomas Blankenstein
Published in: Current Opinion in Immunology, Issue Vol. 74, 2022, Page(s) 18-24, ISSN 0952-7915
Publisher: Elsevier BV
DOI: 10.1016/j.coi.2021.09.005

Immune Phenotypes and Target Antigens of ClonallyExpanded Bone Marrow T Cells in Treatment-NaïveMultiple Myeloma

Author(s): Carlotta Welters1, María Fernanda Lammoglia Cobo1, Christian Alexander Stein1, Meng-Tung Hsu2, Amin Ben Hamza1, Livius Penter1,3, Xiaojing Chen2, Christopher Buccitelli4, Oliver Popp4, Philipp Mertins4, Kerstin Dietze1, Lars Bullinger1,5, Andreas Moosmann6,7, Eric Blanc8, Dieter Beule8, Armin Gerbitz9, Julian Strobel10, Holger Hackstein10, Hans-Peter Rahn11, Klaus Dornmair12, Thomas Blankenstein2
Published in: Cancer Immunology Research, 2022, ISSN 2326-6066
Publisher: American Association for Cancer Research Inc.
DOI: 10.1158/2326-6066.cir-22-0434